FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Dilip Davda recommend to "Avoid" the IPO.
Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
---|---|---|---|---|---|
Count | 0 | 0 | 0 | 1 | 0 |
% | 0.00 | 0.00 | 0.00 | 100.00 | 0.00 |
Reviewer | Recommendation | Past Reviews |
---|---|---|
Dilip Davda | Avoid |
[Dilip Davda] The company operates in a highly competitive and fragmented segment with many players around. The sudden boost in its bottom line for 9M FY23 raises eyebrows and concern over sustainability going forward. Based on such super earnings, the issue appears greedily priced, while based on its track records, it appears exorbitantly priced. There is no harm in skipping this pricey issue. Read detail review...
Vilin Bio Med Limited peer comparison with similar listed entities. () (As on March 31, 2022)
Company Name | EPS (Rs) | NAV (per share) (Rs) | P/E (x) | RoNW (%) |
---|---|---|---|---|
EPS Basic | ||||
Vilin Bio Med Limited | 0.04 | 8.96 | 294.82 | 0.45 |
JFL Life Sciences Limited | 3.77 | 42.66 | 10.82 | 25.20 |
Vaishali Pharma Limited | 3.82 | 24.99 | 33.77 | 15.27 |
Anuh Pharma Limited | 6.10 | 6.10 | 14.70 | 14.30 |
Notes:
Vilin Bio Med IPO Reviews, analysis and views by popular members. Read Vilin Bio Med Limited IPO reviews by retail investors to find recommended ipo to buy.
Post Recommendation Manage Your IPO Reviews
Review By | Apply | May Apply | Neutral | Avoid |
---|---|---|---|---|
Count | 0 | 0 | 1 | 1 |
% | 0.00 | 0.00 | 50.00 | 50.00 |
Member | Review |
---|---|
IPO LEADER IPO Mentor (800+ Posts, 400+ Likes) |
Avoid Avoid June 21, 2023 6:42:33 AM |
hiteshhastimal |
Neutral Kya lagta hai doston June 12, 2023 2:20:15 PM |
Post Recommendation Manage Recommendations
Note:
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|